Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F-DOPA.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C (+9 more)
Abstract
Purpose & methodsNeuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using ⁶⁸Ga-DOTA-conjugated peptides, as well as ¹⁸F-DOPA imaging for various neuroendocrine neoplasms.Results & conclusionThe previous procedural guideline by EANM regarding the use PET/CT tumour imaging with ⁶⁸Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.